Literature DB >> 10496352

Potent interaction of flavopiridol with MRP1.

J H Hooijberg1, H J Broxterman, G L Scheffer, C Vrasdonk, M Heijn, M C de Jong, R J Scheper, J Lankelma, H M Pinedo.   

Abstract

The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its antiproliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC4/ADR. The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 microM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496352      PMCID: PMC2362861          DOI: 10.1038/sj.bjc.6690687

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

1.  An improved assay for nanomole amounts of inorganic phosphate.

Authors:  P A Lanzetta; L J Alvarez; P S Reinach; O A Candia
Journal:  Anal Biochem       Date:  1979-11-15       Impact factor: 3.365

2.  Saturation reversal of the multidrug pump using many reversers in low-dose combinations.

Authors:  E Lyubimov; L B Lan; I Pashinsky; S Ayesh; W D Stein
Journal:  Anticancer Drugs       Date:  1995-12       Impact factor: 2.248

3.  Reduction of disulfide-containing amines amino acids, and small peptides.

Authors:  J Bulter; S P Spielberg; J D Schulman
Journal:  Anal Biochem       Date:  1976-10       Impact factor: 3.365

4.  ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene.

Authors:  D W Loe; R K Stewart; T E Massey; R G Deeley; S P Cole
Journal:  Mol Pharmacol       Date:  1997-06       Impact factor: 4.436

5.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Authors:  W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

Review 6.  The flavonoids. A class of semi-essential food components: their role in human nutrition.

Authors:  J Kühnau
Journal:  World Rev Nutr Diet       Date:  1976       Impact factor: 0.575

7.  Disposition of quercetin in man after single oral and intravenous doses.

Authors:  R Gugler; M Leschik; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

8.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Authors:  B A Carlson; M M Dubay; E A Sausville; L Brizuela; P J Worland
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

Review 9.  Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP.

Authors:  S P Cole; R G Deeley
Journal:  Bioessays       Date:  1998-11       Impact factor: 4.345

10.  Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers.

Authors:  P C Hollman; J H de Vries; S D van Leeuwen; M J Mengelers; M B Katan
Journal:  Am J Clin Nutr       Date:  1995-12       Impact factor: 7.045

View more
  7 in total

Review 1.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.

Authors:  Don G Morris; Vivien H C Bramwell; Robert Turcotte; Alvaro T Figueredo; Martin E Blackstein; Shail Verma; Sarah Matthews; Elizabeth A Eisenhauer
Journal:  Sarcoma       Date:  2006

3.  Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells.

Authors:  Xiaoran Li; Jie Lu; Quancheng Kan; Xiaoli Li; Qiong Fan; Yaqing Li; Ruixia Huang; Ana Slipicevic; Hiep Phuc Dong; Lars Eide; Junbai Wang; Hongquan Zhang; Viktor Berge; Mariusz Adam Goscinski; Gunnar Kvalheim; Jahn M Nesland; Zhenhe Suo
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

4.  A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.

Authors:  Vivian Osei Poku; Surtaj Hussain Iram
Journal:  PeerJ       Date:  2022-01-05       Impact factor: 2.984

Review 5.  Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.

Authors:  Kohji Noguchi; Kazuhiro Katayama; Yoshikazu Sugimoto
Journal:  Pharmgenomics Pers Med       Date:  2014-02-05

6.  Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.

Authors:  Burak Cem Soner; Huseyin Aktug; Eda Acikgoz; Fahriye Duzagac; Ummu Guven; Sule Ayla; Cag Cal; Gulperi Oktem
Journal:  Int J Mol Med       Date:  2014-09-11       Impact factor: 4.101

7.  Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids.

Authors:  Olga Wesołowska; Andrzej B Hendrich; Barbara Łaniapietrzak; Jerzy Wiśniewski; Joseph Molnar; Imre Ocsovszki; Krystyna Michalak
Journal:  Cell Mol Biol Lett       Date:  2008-11-19       Impact factor: 5.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.